Informed Prostate Cancer Patient Support

Single‐cell analysis of localized prostate cancer patients links high Gleason score with an immunosuppressive profile - Adorno Febles - The Prostate - Wiley Online Library Victor R. Adorno Febles MD ,  Yuan Hao PhD ,  Aarif Ahsan PhD ,  Jiansheng Wu PhD ,  Yingzhi Qian MA ,  Hua Zhong PhD ,  Stacy Loeb MD ,  Danil V. Makarov MD ,  Herbert Lepor MD … See all authors First published: 29 March 2023 https://doi.org/10.1002/pros.24524 Victor R. Adorno Febles and Yuan Hao are the co-primary authors of this study. Abstract Background Evading immune surveillance is a hallmark for the development of multiple cancer types. Whether immune evasion contributes to the pathogenesis of high-grade prostate cancer (HGPCa) remains an area of active inquiry.

Every-other-day vs once-a-week urethra-sparing prostate SBRT: 5-year results of a randomized phase II trial - ScienceDirect Every-other-day vs once-a-week urethra-sparing prostate SBRT: 5-year results of a randomized phase II trial Author links open overlay panel , , , , , , , , , , , https://doi.org/10.1016/j.ijrobp.2023.03.057 Get rights and content ABSTRACT Purpose To present the 5-year results from a prospective multicenter phase II randomized trial of every-other-day (EOD) vs. once-a-week (QW) urethra-sparing stereotactic body radiotherapy (SBRT) for localized prostate cancer. Materials/Methods Between 2012 and 2015, 170 patients from nine European institutions with cT1c-3aN0M0 prostate cancer were randomized to 36.25 Gy in 5 fractions (6.5 Gy/fraction to the urethra) delivered either EOD (arm A, n=84), or QW (arm B, n=86). The median follow-up was 78 months (interquartile range, IQR 23 months) and 77 months (IQR 16 months) for arms A and B, respectively. Results Among th

ENZAMET shows promise as prostate cancer treatment medicalxpress.com ENZAMET shows promise as prostate cancer treatment Science X 5–6 minutes Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia, CC BY-SA 3.0 A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates. The results from the clinical trial of ENZAMET, co-chaired by Professor Christopher Sweeney, Director of the South Australian immunoGENomics Cancer Institute (SAiGENCI) that operates within the University of Adelaide, have been published today in The Lancet Oncology . For people with metastatic hormone-s

Clinical and Molecular Determinants of PSA Response to Bipolar Androgen Therapy in Prostate Cancer - Caputo - The Prostate - Wiley Online Library

Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: performance of a fully automated AI‐algorithm for lesion detection and classification - Oerther - The Prostate - Wiley Online Library

Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era | Prostate Cancer and Prostatic Diseases

P‐score in preoperative biopsies accurately predicts P‐score in final pathology at radical prostatectomy in patients with localized prostate cancer - Röbeck - The Prostate - Wiley Online Library onlinelibrary.wiley.com P‐score in preoperative biopsies accurately predicts P‐score in final pathology at radical prostatectomy in patients with localized prostate cancer Pontus Röbeck MD 40–50 minutes 1 INTRODUCTION Prostate cancer (PCa) is a highly heterogeneous multifocal disease, ranging from indolent, clinically insignificant lesions that can be managed with active surveillance or watchful waiting, to aggressive tumors requiring curative therapy such as radical prostatectomy (RP) or radiotherapy (RT). Identifying clinically significant PCa is challenging, 1 which complicates the choice of adequate treatment. Consequently, many PCa patients ar

Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real‐life experience of ADT in Asia (READT) study - Wong - The Prostate - Wiley Online Library :  onlinelibrary.wiley.com Chris H. M. Wong ,  Corresponding Author Chris H. M. Wong cuhk.chriswong@gmail.com orcid.org/0000-0003-1795-1198 Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, Hong Kong Department of Surgery, Division of Urology, Prince of Wales Hospital, Shatin, Hong Kong Correspondence Chris H. M. Wong Email: cuhk.chriswong@gmail.com Search for more papers by this author Ning Xu MD ,  Ning Xu MD Department of Surge